Orphan designation: Rivoceranib (mesilate) Treatment of hepatocellular carcinoma, 25/07/2024 Positive

Orphan designation: camrelizumab Treatment of hepatocellular carcinoma, 25/07/2024 Positive

Orphan designation: Heterologous swine glyco-humanised polyclonal antibody against T lymphocytes Treatment of peripheral T-cell lymphoma, 25/07/2024 Positive

Human medicines European public assessment report (EPAR): Tauvid, Flortaucipir (18F), Date of authorisation: 22/08/2024, Status: Authorised

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - September 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 September 2024, 10:00 (CEST) to 18 September 2024, 12:00 (CEST)

Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (18 September 2024)

Orphan designation: Cannabidiol acid methyl ester Treatment of Prader-Willi syndrome, 25/07/2024 Positive

EMEA-003316-PIP01-22

Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 5, Status: Authorised

EMEA-003331-PIP02-23